NEW ENGLAND CENTER FOR PSYCHIATRIC TREATMENT AND EDUCATION

SIMON EPSTEIN, M.D.
91 STRAWBERRY HILL AVE. #140
STAMFORD, CT 06902
203-348-8579

Monthly NewsNotes

Monthly NewsNote

May 2004

Email this article to a friend

ANTIDEPRESSANTS, SUICIDAL THOUGHTS, AND THE FDA

There has been a great deal of publicity recently related to the potential of antidepressants to cause suicidal ideas or even suicide. This, of course, has created a great deal of anxiety in parents when an antidepressant is recommended for their child. Therefore, I will use this note to put the subject into perspective and thus hopefully, reduce the anxiety.

Not long ago the British concluded that SSRI antidepressants (Prozac, Zoloft, etc.) could increase the likelihood of suicide, and recommend against their use. The one exception was Prozac. I don’t know where this stands in England, but here’s the situation in the U.S.

We were told by the FDA not to start patients under 18 on Effexor or Paxil. However, anyone currently on either of those medications could continue to use them. At that time the FDA indicated concerns about the other antidepressant medications, but nothing was done. In fact, Dr. Thomas Laughren, Chief of the FDA Pharmacology Group said, “We don’t know if there is a link between antidepressants and suicide.”

However, the FDA has now asked the drug companies to include a warning in the package inserts for all commonly used antidepressants. This now includes both children AND adults.

What does this really mean? We treat many serious conditions with these medications, leading to an improved life, a better mood, and a higher level of functioning. Those of us who use these medications regularly know that they occasionally cause “dis-inhibition” That means that a patient may become more agitated or aggressive because of the medication, in which case it will have to be discontinued. We also know that as a suicidal patient begins to get better there is a danger zone through which they pass on the way to getting well. This means that now, as before, there needs to be good follow up of the patient, particularly during the first two weeks.

We have always been careful. Perhaps we will be more careful. But I think we must be careful not to jump to conclusions before the research is complete and the facts known. If you remember, a few years ago there was a storm over Prozac, almost leading to it becoming unavailable. When the FDA studied the material, it was found to be lacking in credibility, and the storm passed. And now, Prozac is the recommended drug.

When we treat patients it is for a good reason, and certainly antidepressants have prevented an untold number of suicides. These medications are also approved for PTSD, Obsessive Compulsive Disorder, and Generalized Anxiety Disorder. These are all serious problems.

Therefore, I recommend that the medications be used as clinically indicated, perhaps with some extra care, until research material is available. These are very important medications, and in most cases it will hurt the patients if their use is curtailed.

Back to top